These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 30566494)

  • 21. Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009.
    Al Shaer L; AbdulRahman M; John TJ; AlHashimi A
    Transfusion; 2012 Nov; 52(11):2300-9. PubMed ID: 22691239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reassessment of hepatitis B virus window periods for two transcription-mediated amplification assays using screening data of South African blood donors.
    Vermeulen M; van Drimmelen H; Coleman C; Sykes W; Reddy R; Busch M; Kleinman S; Lelie N
    Transfusion; 2019 Sep; 59(9):2922-2930. PubMed ID: 31265759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Safe blood in the absence of viral infections due to HBV, HCV and HIV in serological window period in donors].
    Contreras AM; Reta CB; Torres O; Celis A; Domínguez J
    Salud Publica Mex; 2011; 53 Suppl 1():S13-8. PubMed ID: 21877067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marked reduction in the incidence of transfusion-transmitted hepatitis B virus infection after the introduction of antibody to hepatitis B core antigen and individual donation nucleic acid amplification screening in Japan.
    Tanaka A; Yamagishi N; Hasegawa T; Miyakawa K; Goto N; Matsubayashi K; Satake M
    Transfusion; 2023 Nov; 63(11):2083-2097. PubMed ID: 37767806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of hepatitis B virus infection in German blood donors 2008-2015.
    Scheiblauer H; Heiden M; Funk M; Oberle D; Kreß J; Jork C; Chudy M
    Vox Sang; 2020 Apr; 115(3):152-161. PubMed ID: 32023664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human immunodeficiency virus-1 and hepatitis C virus RNA among South African blood donors: estimation of residual transfusion risk and yield of nucleic acid testing.
    Fang CT; Field SP; Busch MP; Heyns Adu P
    Vox Sang; 2003 Jul; 85(1):9-19. PubMed ID: 12823725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test.
    Kleinman SH; Strong DM; Tegtmeier GG; Holland PV; Gorlin JB; Cousins C; Chiacchierini RP; Pietrelli LA
    Transfusion; 2005 Aug; 45(8):1247-57. PubMed ID: 16078909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy.
    Kuhns MC; Kleinman SH; McNamara AL; Rawal B; Glynn S; Busch MP;
    Transfusion; 2004 Sep; 44(9):1332-9. PubMed ID: 15318857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A method for estimating the residual risk of transfusion-transmitted HBV infection associated with occult hepatitis B virus infection in a donor population without universal anti-HBc screening.
    Seed CR; Kiely P
    Vox Sang; 2013 Nov; 105(4):290-8. PubMed ID: 23802710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan.
    Taira R; Satake M; Momose S; Hino S; Suzuki Y; Murokawa H; Uchida S; Tadokoro K
    Transfusion; 2013 Jul; 53(7):1393-404. PubMed ID: 23033944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of blood donor screening by HIV, HCV, HBV-NAT assays, as well as HBsAg and anti-HBc immunoassays in Germany (2008-2015).
    Fiedler SA; Oberle D; Chudy M; Scheiblauer H; Henseler O; Halbauer J; Heiden M; Funk M
    Vox Sang; 2019 Jul; 114(5):443-450. PubMed ID: 31012114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged incubation period of hepatitis B in a recipient of a nucleic acid amplification test-negative hepatitis B virus window donation.
    Matsuno T; Matsuura H; Fujii S; Tanaka A; Satake M; Kinoshita T; Tomita A; Matsui Y; Sugiura Y; Miura Y
    Transfusion; 2021 Sep; 61(9):2782-2787. PubMed ID: 34258757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct comparison of three residual risk models for hepatitis B virus window period infections using updated input parameters.
    Lelie N; Vermeulen M; van Drimmelen H; Coleman C; Bruhn R; Reddy R; Busch M; Kleinman S
    Vox Sang; 2020 Apr; 115(3):133-145. PubMed ID: 31960480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence, incidence and residual risk of transfusion transmitted viruses (HBV, HCV and HIV infections) in Lithuanian blood donors from 2004 to 2018: The incidence/window-period model study.
    Grubyte S; Urboniene J; Nedzinskiene L; Jelinskaite A; Zagminas K; Ambrozaitis A; Jancoriene L
    PLoS One; 2021; 16(2):e0246704. PubMed ID: 33606700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Occult hepatitis B infection and transfusion-transmission risk.
    Candotti D; Boizeau L; Laperche S
    Transfus Clin Biol; 2017 Sep; 24(3):189-195. PubMed ID: 28673499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence, incidence and residual risk of transfusion-transmitted hepatitis B virus infection in Italy from 2009 to 2018.
    Velati C; Romanò L; Pati I; Marano G; Piccinini V; Catalano L; Pupella S; Vaglio S; Veropalumbo E; Masiello F; Pisani G; Grazzini G; Zanetti A; Liumbruno GM
    Blood Transfus; 2019 Nov; 17(6):409-417. PubMed ID: 31846606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
    Vermeulen M; Lelie N; Sykes W; Crookes R; Swanevelder J; Gaggia L; Le Roux M; Kuun E; Gulube S; Reddy R
    Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction of the risk of transfusion-transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa: a 5-year review.
    Cable R; Lelie N; Bird A
    Vox Sang; 2013 Feb; 104(2):93-9. PubMed ID: 22924987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
    Hourfar MK; Jork C; Schottstedt V; Weber-Schehl M; Brixner V; Busch MP; Geusendam G; Gubbe K; Mahnhardt C; Mayr-Wohlfart U; Pichl L; Roth WK; Schmidt M; Seifried E; Wright DJ;
    Transfusion; 2008 Aug; 48(8):1558-66. PubMed ID: 18466173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fifteen years of Nucleic Acid Testing in France: Results and lessons.
    Laperche S; Tiberghien P; Roche-Longin C; Pillonel J
    Transfus Clin Biol; 2017 Sep; 24(3):182-188. PubMed ID: 28709845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.